Area of research
Pulmonary and Respiratory Medicine · Pathology and Forensic Medicine
Research interest
Research interests include Medicine, Pirfenidone, Idiopathic pulmonary fibrosis, Placebo, Internal medicine, and Discontinuation.
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study
SAT0433 Safety and Tolerability of Pirfenidone in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease – the Lotuss Study
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis
All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials
Comprehensive assessment of the long‐term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis